234 related articles for article (PubMed ID: 18079436)
1. Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy.
Delobel P; Lavenir I; Fraser G; Ingram E; Holzer M; Ghetti B; Spillantini MG; Crowther RA; Goedert M
Am J Pathol; 2008 Jan; 172(1):123-31. PubMed ID: 18079436
[TBL] [Abstract][Full Text] [Related]
2. Assembly of transgenic human P301S Tau is necessary for neurodegeneration in murine spinal cord.
Macdonald JA; Bronner IF; Drynan L; Fan J; Curry A; Fraser G; Lavenir I; Goedert M
Acta Neuropathol Commun; 2019 Mar; 7(1):44. PubMed ID: 30885267
[TBL] [Abstract][Full Text] [Related]
3. Role of caspase-3 in tau truncation at D421 is restricted in transgenic mouse models for tauopathies.
Zhang Q; Zhang X; Chen J; Miao Y; Sun A
J Neurochem; 2009 Apr; 109(2):476-84. PubMed ID: 19200347
[TBL] [Abstract][Full Text] [Related]
4. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein.
Allen B; Ingram E; Takao M; Smith MJ; Jakes R; Virdee K; Yoshida H; Holzer M; Craxton M; Emson PC; Atzori C; Migheli A; Crowther RA; Ghetti B; Spillantini MG; Goedert M
J Neurosci; 2002 Nov; 22(21):9340-51. PubMed ID: 12417659
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylated p38MAPK specific antibodies cross-react with sarkosyl-insoluble hyperphosphorylated tau proteins.
Sahara N; Vega IE; Ishizawa T; Lewis J; McGowan E; Hutton M; Dickson D; Yen SH
J Neurochem; 2004 Aug; 90(4):829-38. PubMed ID: 15287888
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine Increases Tau Phosphorylation, Truncation and Oligomerization.
Shirafuji N; Hamano T; Yen SH; Kanaan NM; Yoshida H; Hayashi K; Ikawa M; Yamamura O; Kuriyama M; Nakamoto Y
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562600
[TBL] [Abstract][Full Text] [Related]
7. Cell-cycle markers in a transgenic mouse model of human tauopathy: increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1.
Delobel P; Lavenir I; Ghetti B; Holzer M; Goedert M
Am J Pathol; 2006 Mar; 168(3):878-87. PubMed ID: 16507903
[TBL] [Abstract][Full Text] [Related]
8. Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice.
Ohia-Nwoko O; Montazari S; Lau YS; Eriksen JL
Mol Neurodegener; 2014 Nov; 9():54. PubMed ID: 25432085
[TBL] [Abstract][Full Text] [Related]
9. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.
Zhang Q; Zhang X; Sun A
Acta Neuropathol; 2009 Jun; 117(6):687-97. PubMed ID: 19190923
[TBL] [Abstract][Full Text] [Related]
10. Increase in tau tyrosine phosphorylation correlates with the formation of tau aggregates.
Vega IE; Cui L; Propst JA; Hutton ML; Lee G; Yen SH
Brain Res Mol Brain Res; 2005 Aug; 138(2):135-44. PubMed ID: 15913839
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation and oligomerization of α-synuclein associated with GSK-3β activation in the rTg4510 mouse model of tauopathy.
Takaichi Y; Chambers JK; Inoue H; Ano Y; Takashima A; Nakayama H; Uchida K
Acta Neuropathol Commun; 2020 Jun; 8(1):86. PubMed ID: 32560668
[TBL] [Abstract][Full Text] [Related]
12. The ordered assembly of tau is the gain-of-toxic function that causes human tauopathies.
Goedert M
Alzheimers Dement; 2016 Oct; 12(10):1040-1050. PubMed ID: 27686274
[TBL] [Abstract][Full Text] [Related]
13. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy.
Mocanu MM; Nissen A; Eckermann K; Khlistunova I; Biernat J; Drexler D; Petrova O; Schönig K; Bujard H; Mandelkow E; Zhou L; Rune G; Mandelkow EM
J Neurosci; 2008 Jan; 28(3):737-48. PubMed ID: 18199773
[TBL] [Abstract][Full Text] [Related]
14. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice.
Ozcelik S; Fraser G; Castets P; Schaeffer V; Skachokova Z; Breu K; Clavaguera F; Sinnreich M; Kappos L; Goedert M; Tolnay M; Winkler DT
PLoS One; 2013; 8(5):e62459. PubMed ID: 23667480
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
Pérez M; Ribe E; Rubio A; Lim F; Morán MA; Ramos PG; Ferrer I; Isla MT; Avila J
Neuroscience; 2005; 130(2):339-47. PubMed ID: 15664690
[TBL] [Abstract][Full Text] [Related]
17. CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.
Zilka N; Korenova M; Kovacech B; Iqbal K; Novak M
Acta Neuropathol; 2010 Jun; 119(6):679-87. PubMed ID: 20379729
[TBL] [Abstract][Full Text] [Related]
18. Human Truncated Tau Induces Mature Neurofibrillary Pathology in a Mouse Model of Human Tauopathy.
Zimova I; Brezovakova V; Hromadka T; Weisova P; Cubinkova V; Valachova B; Filipcik P; Jadhav S; Smolek T; Novak M; Zilka N
J Alzheimers Dis; 2016 Sep; 54(2):831-43. PubMed ID: 27567836
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ.
Cho JH; Johnson GV
J Biol Chem; 2004 Dec; 279(52):54716-23. PubMed ID: 15494420
[TBL] [Abstract][Full Text] [Related]
20. Conformation determines the seeding potencies of native and recombinant Tau aggregates.
Falcon B; Cavallini A; Angers R; Glover S; Murray TK; Barnham L; Jackson S; O'Neill MJ; Isaacs AM; Hutton ML; Szekeres PG; Goedert M; Bose S
J Biol Chem; 2015 Jan; 290(2):1049-65. PubMed ID: 25406315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
